IL208654A0 - Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors - Google Patents

Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors

Info

Publication number
IL208654A0
IL208654A0 IL208654A IL20865410A IL208654A0 IL 208654 A0 IL208654 A0 IL 208654A0 IL 208654 A IL208654 A IL 208654A IL 20865410 A IL20865410 A IL 20865410A IL 208654 A0 IL208654 A0 IL 208654A0
Authority
IL
Israel
Prior art keywords
ikk
threonine
protein kinase
kinase inhibitors
beta serine
Prior art date
Application number
IL208654A
Other languages
English (en)
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0807642A external-priority patent/GB0807642D0/en
Priority claimed from GB0815550A external-priority patent/GB0815550D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of IL208654A0 publication Critical patent/IL208654A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
IL208654A 2008-04-26 2010-10-12 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors IL208654A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0807642A GB0807642D0 (en) 2008-04-26 2008-04-26 IKK- serine-threonine protein kinase inhibitors
GB0815550A GB0815550D0 (en) 2008-08-27 2008-08-27 IKK-beta serine-threonine protein kinase inhibitors
PCT/GB2009/001051 WO2009130475A1 (en) 2008-04-26 2009-04-23 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IL208654A0 true IL208654A0 (en) 2010-12-30

Family

ID=40786701

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208654A IL208654A0 (en) 2008-04-26 2010-10-12 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors

Country Status (13)

Country Link
US (1) US20110046210A1 (enExample)
EP (1) EP2285797A1 (enExample)
JP (1) JP2011518817A (enExample)
KR (1) KR20110020784A (enExample)
CN (1) CN102036980A (enExample)
AU (1) AU2009239772A1 (enExample)
BR (1) BRPI0911480A2 (enExample)
CA (1) CA2722660A1 (enExample)
EA (1) EA201001708A1 (enExample)
IL (1) IL208654A0 (enExample)
MX (1) MX2010011643A (enExample)
WO (1) WO2009130475A1 (enExample)
ZA (1) ZA201008027B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012176930A (ja) * 2010-10-07 2012-09-13 Santen Pharmaceut Co Ltd ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
DK3222616T3 (da) 2012-10-17 2019-08-19 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluorbenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorphenyl}ethyl]-L-alanin og terbutylester deraf
EA028858B9 (ru) 2013-02-06 2018-06-29 Байер Кропсайенс Акциенгезельшафт Галогензамещенные производные пиразола в качестве средств борьбы с вредителями
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
ATE522516T1 (de) * 2006-11-01 2011-09-15 Chroma Therapeutics Ltd Inhibitoren der ikk-beta-serin-threonin- proteinkinase
WO2008053185A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE

Also Published As

Publication number Publication date
BRPI0911480A2 (pt) 2018-04-03
MX2010011643A (es) 2010-11-30
JP2011518817A (ja) 2011-06-30
US20110046210A1 (en) 2011-02-24
KR20110020784A (ko) 2011-03-03
AU2009239772A1 (en) 2009-10-29
ZA201008027B (en) 2011-07-27
CA2722660A1 (en) 2009-10-29
EP2285797A1 (en) 2011-02-23
EA201001708A1 (ru) 2011-06-30
CN102036980A (zh) 2011-04-27
WO2009130475A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
IL211693A0 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL257083B (en) The history of phosphorus as kinase inhibitors
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL206358A0 (en) Pyrrolopyrazine kinase inhibitors
IL209258A0 (en) Pyrrolopyridines as kinase inhibitors
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
ZA201202776B (en) Imidazole derivatives as casein kinase inhibitors
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
ZA201008027B (en) Substituted thiophenecarboxamides as ikk-beta serine-,threonine-protein kinase inhibitors
GB0914726D0 (en) Kinase inhibitors
GB0807908D0 (en) ikk-beta serine-theronine protein kinase inhibitors
ZA201004903B (en) Pyrrolopyrazine kinase inhibitors
GB0815550D0 (en) IKK-beta serine-threonine protein kinase inhibitors